{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:08:53Z","timestamp":1791950933685,"version":"4.3.4"},"reference-count":68,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The best frontline treatment for acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs) is unclear. To support a clinical practice guideline, we systematically reviewed and meta-analyzed evidence on (1) asparaginase-based (pediatric) vs non\u2013asparaginase-based (adult) regimens and (2) allogeneic hematopoietic stem cell transplantation (HSCT) vs no HSCT for AYAs (aged 15-39 years) with ALL in first complete remission. Data sources were PubMed, CINAHL, and PsycINFO from inception to 29 November 2023. Eligible studies compared regimens or the use of HSCT and reported survival, remission, toxicity, or quality of life in AYAs. We included 19 studies (14 comparative, 5 single-group; N = 3607) comparing regimens and 7 studies (N = 7492) comparing HSCT and no HSCT. Studies were mostly of poor quality, with sparse randomized controlled trials (RCTs), yielding low-certainty findings. Pediatric regimens were associated with higher 5-year overall survival (OS; relative risk [RR], 1.40; 95% confidence interval [CI], 1.18-1.65), event-free survival (RR, 1.80; 95% CI, 1.13-2.85), disease-free survival (DFS; RR, 1.55; 95% CI, 1.32-1.82), and lower treatment-related mortality (TRM; RR, 0.29; 95% CI, 0.09-0.90). HSCT was associated with lower 5-year OS (RR, 0.72; 95% CI, 0.61-0.84) and DFS (RR, 0.78; 95% CI, 0.68-0.90) and higher nonrelapse mortality (RR, 2.70; 95% CI, 1.18-6.18) and TRM (hazard ratio, 6.88; 95% CI, 3.02-15.70). Relapse risk varied by time point. In AYAs with Philadelphia chromosome\u2013negative ALL, pediatric regimens may improve survival; toxicity-related evidence remains limited. HSCT may lead to inferior OS and DFS. With a dearth of RCTs, low-certainty evidence highlights the need for high-quality studies and subanalyses of AYAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018736","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:14:26Z","timestamp":1769717666000},"page":"3664-3675","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-4561","authenticated-orcid":false,"given":"Yuliia","family":"Sereda","sequence":"first","affiliation":[{"name":"1Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1357-1088","authenticated-orcid":false,"given":"Htun Ja","family":"Mai","sequence":"additional","affiliation":[{"name":"1Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4910-9656","authenticated-orcid":false,"given":"Ghid","family":"Kanaan","sequence":"additional","affiliation":[{"name":"1Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7498-3827","authenticated-orcid":false,"given":"John W.","family":"Melson","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Oncology, and Palliative Care, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-391X","authenticated-orcid":false,"given":"Teruhiko","family":"Terasawa","sequence":"additional","affiliation":[{"name":"3Department of Emergency and General Internal Medicine, Fujita Health University, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-5872","authenticated-orcid":false,"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"5Comprehensive Cancer Center, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-2239","authenticated-orcid":false,"given":"Julie A.","family":"Wolfson","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology-Oncology, The University of Alabama at Birmingham, Birmingham, AL"},{"name":"7Institute for Cancer Outcomes and Survivorship, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2062-3382","authenticated-orcid":false,"given":"Ian J.","family":"Saldanha","sequence":"additional","affiliation":[{"name":"8Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"},{"name":"9Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-7290","authenticated-orcid":false,"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[{"name":"1Center for Evidence Synthesis in Health, Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"12","key":"2026052610372316400_bib1","first-page":"e49930","article-title":"A review of acute lymphocytic leukemia (ALL) in the pediatric population: evaluating current trends and changes in guidelines in the past decade","volume":"15","author":"Ekpa","year":"2023","journal-title":"Cureus"},{"issue":"9881","key":"2026052610372316400_bib2","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2026052610372316400_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.23.01367","article-title":"Survival trends among adolescents and young adults diagnosed with cancer in the United States: comparisons with children and older adults","volume":"42","author":"Keegan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052610372316400_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14740\/jh1282","article-title":"Disparities in acute lymphocytic leukemia outcomes among young adults","volume":"13","author":"McKinnell","year":"2024","journal-title":"J Hematol"},{"issue":"9","key":"2026052610372316400_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.6004\/jnccn.2012.0117","article-title":"Adolescent and young adult oncology. Clinical practice guidelines in oncology","volume":"10","author":"Coccia","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"2026052610372316400_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cncr.29870","article-title":"Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future","volume":"122","author":"Smith","year":"2016","journal-title":"Cancer"},{"key":"2026052610372316400_bib7","unstructured":"US Department of Health and Human Services, National Cancer Institute and LIVESTRONG Young Adult Alliance. Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer. Report of Adolescent and Young Adult Oncology Progress Review Group. National Cancer Institute. 2006. Accessed 16 December 2025. https:\/\/www.cancer.gov\/types\/aya\/research\/ayao-august-2006.pdf."},{"issue":"16","key":"2026052610372316400_bib8","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1200\/JCO.2011.35.5602","article-title":"Delineating the age ranges used to define adolescents and young adults","volume":"29","author":"Geiger","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026052610372316400_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2026052610372316400_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2026052610372316400_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2026052610372316400_bib12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026052610372316400_bib13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"2026052610372316400_bib14","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.3390\/curroncol30090625","article-title":"Pediatric-inspired regimens in the treatment of acute lymphoblastic leukemia in adolescents and young adults: a systematic review","volume":"30","author":"Zeckanovic","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"2026052610372316400_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.2016.145631","article-title":"Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Giebel","year":"2017","journal-title":"Haematologica"},{"issue":"10","key":"2026052610372316400_bib16","first-page":"CD008818","article-title":"Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission","volume":"2011","author":"Pidala","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2026052610372316400_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026052610372316400_bib18","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"2026052610372316400_bib19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006469","article-title":"ASH 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults","author":"DuVall","year":"11  2026","journal-title":"Preprint"},{"key":"2026052610372316400_bib20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026052610372316400_bib21","volume-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","year":"2008"},{"issue":"3","key":"2026052610372316400_bib22","doi-asserted-by":"crossref","first-page":"pkaf033","DOI":"10.1093\/jncics\/pkaf033","article-title":"Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia","volume":"9","author":"Wolfson","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"2026052610372316400_bib23","unstructured":"Cancer care delivery in adolescent and young adult patients with acute lymphoblastic leukemia. ClinicalTrials.gov identifier: NCT03204916. Updated 6 January 2025. Accessed 17 February 2026. https:\/\/clinicaltrials.gov\/search?term=NCT03204916."},{"issue":"2","key":"2026052610372316400_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2026.100222","article-title":"Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemia","volume":"3","author":"Saldanha","year":"2026","journal-title":"Blood Neoplasia"},{"issue":"1","key":"2026052610372316400_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13643-019-1250-y","article-title":"The Systematic Review Data Repository (SRDR): descriptive characteristics of publicly available data and opportunities for research","volume":"8","author":"Saldanha","year":"2019","journal-title":"Syst Rev"},{"key":"2026052610372316400_bib26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026052610372316400_bib27","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2026052610372316400_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.annepidem.2017.10.014","article-title":"Relative rates not relative risks: addressing a widespread misinterpretation of hazard ratios","volume":"28","author":"Sutradhar","year":"2018","journal-title":"Ann Epidemiol"},{"issue":"19","key":"2026052610372316400_bib29","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"2026052610372316400_bib30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"issue":"11","key":"2026052610372316400_bib31","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"2026052610372316400_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"5","key":"2026052610372316400_bib33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026052610372316400_bib34","first-page":"400","article-title":"[Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols]","volume":"149","author":"de Bont","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"3","key":"2026052610372316400_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2026052610372316400_bib36","first-page":"485","article-title":"[Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol]","volume":"144","author":"Lopez-Hernandez","year":"2008","journal-title":"Gac Med Mex"},{"issue":"5","key":"2026052610372316400_bib37","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2026052610372316400_bib38","first-page":"8","article-title":"[Results of the treatment of adult acute lymphoblastic leukemia according to ALL-2005 protocol as a basis for new trials]","volume":"81","author":"Parovichnikova","year":"2009","journal-title":"Ter Arkh"},{"issue":"10","key":"2026052610372316400_bib39","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/bcj.2014.72","article-title":"Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group","volume":"4","author":"Hayakawa","year":"2014","journal-title":"Blood Cancer J"},{"issue":"23","key":"2026052610372316400_bib40","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"2026052610372316400_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2026052610372316400_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/10428194.2016.1222376","article-title":"Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia","volume":"58","author":"Kliman","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026052610372316400_bib43","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cam4.2096","article-title":"The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: an IMPACT cohort study","volume":"8","author":"Gupta","year":"2019","journal-title":"Cancer Med"},{"issue":"14","key":"2026052610372316400_bib44","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026052610372316400_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-019-02678-y","article-title":"Outcomes of adult acute lymphoblastic leukemia in the era of pediatric-inspired regimens: a single-center experience","volume":"110","author":"Tantiworawit","year":"2019","journal-title":"Int J Hematol"},{"issue":"5","key":"2026052610372316400_bib46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.16242","article-title":"Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients","volume":"188","author":"Kim","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2026052610372316400_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clml.2020.07.017","article-title":"Comparison of two pediatric-inspired regimens to hyper-CVAD in Hispanic adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Almanza-Huante","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2026052610372316400_bib48","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1182\/bloodadvances.2021005576","article-title":"An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL","volume":"5","author":"Greenwood","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026052610372316400_bib49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.26066","article-title":"Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial","volume":"96","author":"Testi","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2026052610372316400_bib50","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41375-021-01460-6","article-title":"Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232","volume":"36","author":"Burke","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2026052610372316400_bib51","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jfma.2021.07.019","article-title":"Outcome of young adult patients with very-high-risk acute lymphoblastic leukemia treated with pediatric-type chemotherapy - a single institute experience","volume":"121","author":"Cheng","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"2026052610372316400_bib52","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41409-022-01595-9","article-title":"Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult ALL in first complete remission","volume":"57","author":"Haroon","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2026052610372316400_bib53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/jayao.2018.0140","article-title":"Hematopoietic cell transplantation in young adult acute lymphoblastic leukemia: a United States population-level analysis","volume":"8","author":"Muffly","year":"2019","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"7","key":"2026052610372316400_bib54","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","article-title":"Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2026052610372316400_bib55","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"16","key":"2026052610372316400_bib56","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2026052610372316400_bib57","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11684-017-0506-y","article-title":"Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"11","author":"Lou","year":"2017","journal-title":"Front Med"},{"issue":"4","key":"2026052610372316400_bib58","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.21873\/anticanres.13298","article-title":"Effect of stem cell transplant on survival in adult patients with acute lymphoblastic leukemia: NCDB analysis","volume":"39","author":"Master","year":"2019","journal-title":"Anticancer Res"},{"issue":"35","key":"2026052610372316400_bib59","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052610372316400_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00432-019-02854-x","article-title":"Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002","volume":"145","author":"Karachunskiy","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026052610372316400_bib61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2021.08.025","article-title":"How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review","volume":"157","author":"Brigitha","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026052610372316400_bib62","doi-asserted-by":"crossref","first-page":"796426","DOI":"10.3389\/fped.2021.796426","article-title":"Haematopoietic stem cell transplantation in adolescents and young adults with acute lymphoblastic leukaemia: special considerations and challenges","volume":"9","author":"Calvo","year":"2021","journal-title":"Front Pediatr"},{"issue":"17","key":"2026052610372316400_bib63","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.3390\/jcm10173790","article-title":"The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia","volume":"10","author":"Algeri","year":"2021","journal-title":"J Clin Med"},{"issue":"19","key":"2026052610372316400_bib64","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2026052610372316400_bib65","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cancers15133346","article-title":"Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond","volume":"15","author":"Aureli","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026052610372316400_bib66","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/cancers15041349","article-title":"Optimal use of novel immunotherapeutics in B-cell precursor ALL","volume":"15","author":"Lussana","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026052610372316400_bib67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annonc.2023.09.3112","article-title":"ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia","volume":"35","author":"Hoelzer","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"2026052610372316400_bib68","doi-asserted-by":"crossref","first-page":"djw323","DOI":"10.1093\/jnci\/djw323","article-title":"Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies","volume":"109","author":"Yao","year":"2017","journal-title":"J Natl Cancer Inst"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3664\/2519794\/blooda_adv-2025-018736r1-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3664\/2519794\/blooda_adv-2025-018736r1-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:38Z","timestamp":1779806258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3664\/566330\/Pediatric-inspired-regimens-and-HSCT-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018736","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}